Eisai Co. Ltd, National Cancer Institute deal

The institute granted Eisai’s Morphotek Inc. subsidiary exclusive, worldwide rights to develop an undisclosed mouse mAb to treat cancer. The antibody binds to an unknown prostate cancer antigen. Morp...